Skip to main content
    R

    Redhill Biopharma Ltd (RDHL)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $0.36
    -0.01 (-3.87%)

    Market Cap: $3.33M

    Last updated: Nov 17, 2026 at 11:02 AM ET

    Redhill Biopharma Ltd (RDHL) Financials: Revenue, Profit and Cash Flow

    Updated Jun 30, 2026. Financial statements from company filings, amounts in US dollars.

    Redhill Biopharma reported revenue of $286.00K for the fiscal year ended Dec 31, 2025, down 96.4% from the year before. That year, net income was -$429.00K with a net margin of -150.0%, operating cash flow was -$9.65M and free cash flow was -$9.66M. The quarter ended Jun 30, 2026 had net income of -$6.10M.

    Revenue and Margins

    Over the 9 years to Dec 2025, revenue grew from $101.00K, a compound annual rate of 12.3%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$286.00K-96.4%100.0%-2765.4%-150.0%
    Dec 2024$8.04M+23.2%60.3%-181.7%-102.8%
    Dec 2023$6.53M-89.4%47.0%193.4%366.2%
    Dec 2022$61.80M-27.9%46.1%-69.3%-116.0%
    Dec 2021$85.76M+33.2%42.4%-94.6%-114.0%
    Dec 2020$64.36M+923.0%42.7%-99.0%-118.4%
    Dec 2019$6.29M-24.7%64.1%-686.7%-672.5%
    Dec 2018$8.36M+108.6%66.1%-470.5%-464.4%
    Dec 2017$4.01M+3867.3%46.9%-1297.0%-1136.6%
    Dec 2016$101.00KN/A-30140.6%-30240.6%-29079.2%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Jun 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$286.00K$8.04M$6.53M$61.80M$85.76M$64.36M$6.29M$8.36M$4.01M$101.00K
    Cost of revenueN/A$3.19M$3.46M$33.34M$49.41M$36.89M$2.26M$2.84M$2.13M$30.54M
    Gross profit$286.00K$4.85M$3.07M$28.46M$36.35M$27.47M$4.03M$5.52M$1.88M-$30.44M
    Research and development$2.02M$1.59M$3.53M$7.28M$29.50M$16.49M$17.42M$24.86M$32.97M$25.24M
    Operating income-$7.91M-$14.61M$12.63M-$42.84M-$81.14M-$63.68M-$43.20M-$39.33M-$51.97M-$30.54M
    Net income-$429.00K-$8.27M$23.92M-$71.67M-$97.74M-$76.17M-$42.30M-$38.82M-$45.54M-$29.37M
    EBITDA-$7.65M-$7.59M$26.27M-$22.18M-$63.03M-$54.98M-$40.70M-$38.73M-$45.46M-$30.50M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemJun 2026Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022
    RevenueN/A$2.04M$2.04M$2.74M$2.74M$1.29M$1.29M$567.50K$567.50K$1.80M$12.80M$12.80M
    Gross profitN/A$1.24M$1.24M$1.84M$1.84M$584.00K$584.00K$47.00K$47.00K$990.00K$4.20M$4.20M
    Operating income-$4.13M-$2.19M-$2.19M-$3.08M-$3.08M-$4.22M-$4.22M-$6.02M-$6.02M-$4.41M-$9.95M-$9.95M
    Net income-$6.10M-$2.07M-$2.07M-$2.59M-$2.59M-$1.54M-$1.54M-$13.54M-$13.54M$761.00K-$3.73M$2.49M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $170.00K by $3.80M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$25.34M$18.04M$23.05M$158.87M$181.19M$180.24M$74.10M$62.41M$57.34M$74.21M
    Current assets$6.53M$11.91M$16.14M$85.90M$89.15M$70.50M$53.21M$56.79M$51.68M$67.81M
    Cash and equivalents$3.97M$4.62M$5.57M$19.97M$29.47M$29.30M$29.02M$29.00M$16.45M$53.79M
    Total liabilities$21.08M$22.73M$20.98M$207.27M$172.31M$166.38M$14.10M$11.22M$12.28M$11.51M
    Short-term debt$170.00K$353.00K$718.00K$116.25M$1.62M$1.71M$834.00KN/AN/AN/A
    Long-term debtN/AN/AN/AN/A$83.62M$81.39MN/AN/A$448.00K$6.16M
    Shareholder equity$4.27M-$4.68M$2.07M-$48.40M$8.88M$13.86M$60.00M$51.19M$45.06M$62.70M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total assets$26.27M$25.34M$25.34M$25.34M$18.38M$18.38M$18.04M$18.04M$22.02M$22.02M$23.05M$23.05M
    Total liabilities$27.35M$21.08M$21.08M$21.08M$22.79M$22.79M$22.73M$22.73M$21.96M$21.96M$20.98M$20.98M
    Cash and equivalents$5.16M$3.97M$3.97M$1.35M$2.87M$2.87M$4.62M$1.88M$7.28M$7.28M$5.57M$5.57M
    Shareholder equity-$1.08M$4.27M$4.27M$4.27M-$4.41M-$4.41M-$4.68M-$4.68M$61.00K$61.00K$2.07M$2.07M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$9.65M-$9.37M-$35.82M-$29.18M-$65.05M-$48.58M-$40.75M-$34.46M-$44.77M-$28.26M
    Capital expenditures$5.00K$9.00K$11.00K$198.00K$115.00K$53.77M$203.00K$58.00K$1.18M$120.00K
    Free cash flow-$9.66M-$9.38M-$35.83M-$29.38M-$65.16M-$102.35M-$40.95M-$34.52M-$45.95M-$28.38M
    Investing cash flow$1.69M-$9.00K$3.99K$8.30M-$8.14M-$35.65M$5.16M$5.35M-$18.58M$24.47M
    Financing cash flow$7.32M$8.42M$21.38M$11.45M$73.46M$84.37M$35.51M$41.76M$25.65M$36.02M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemJun 2026Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022
    Operating cash flow-$4.56M-$2.51M-$2.51M-$1.59M-$1.59M-$3.09M-$3.09MN/A-$9.02M-$10.59M-$2.42M-$2.42M
    Capital expenditures$14.00K$2.00K$2.00K$4.00K$4.00K$500$500$0$2.00K$7.00KN/A$0
    Free cash flow-$4.58M-$2.51M-$2.51M-$1.60M-$1.60M-$3.09M-$3.09MN/A-$9.02M-$10.60MN/A-$2.42M
    Last 12 quarters

    Frequently Asked Questions About RDHL

    What is Redhill Biopharma's annual revenue?

    Redhill Biopharma reported revenue of $286.00K for the fiscal year ended Dec 31, 2025.

    How fast is Redhill Biopharma's revenue growing?

    Revenue was down 96.4% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was -83.3%.

    Is Redhill Biopharma profitable?

    No. Redhill Biopharma reported net income of -$429.00K for the fiscal year ended Dec 31, 2025, with a net margin of -150.0%.

    How much free cash flow does RDHL generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$9.65M minus capital expenditures of $5.00K produced free cash flow of -$9.66M.

    How much debt does Redhill Biopharma have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $170.00K and cash and equivalents of $3.97M.